Investment Thesis
Xenon is a development-stage pharmaceutical company with a strong balance sheet ($546M cash, minimal debt) providing runway for R&D activities, but deteriorating net losses (-47.6% YoY) and complete revenue absence indicate substantial execution risk. Financial viability depends critically on clinical pipeline advancement and regulatory approval achievements.
Strengths
- Exceptional balance sheet with $546M cash and Debt/Equity of 0.01x
- Superior liquidity position (Current Ratio 27.79x) enabling extended development timeline
- Minimal financial distress risk with low absolute debt load ($11M long-term)
Risks
- Zero revenue with undefined commercialization timeline
- Deteriorating profitability trend (-47.6% YoY net loss decline)
- Unsustainable cash burn rate of ~$89M annually dependent on pipeline success
Key Metrics to Watch
- Operating cash flow burn rate and remaining runway duration
- Clinical trial progression milestones and regulatory pathway status
- Revenue generation or partnership announcements indicating commercial traction
Financial Metrics
Revenue
0.0
Net Income
-102.3M
EPS (Diluted)
$-1.17
Free Cash Flow
-89.0M
Total Assets
1.4B
Cash
545.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-7.6%
ROA
-7.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
27.79x
Quick Ratio
27.79x
Debt/Equity
0.01x
Debt/Assets
3.5%
Interest Coverage
-232.08x
Long-term Debt
10.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T13:57:40.836027 |
Data as of: 2026-03-31 |
Powered by Claude AI